CN113519702A - 鹿角菜岩藻多糖的制备及其在犬猫食品上的应用 - Google Patents
鹿角菜岩藻多糖的制备及其在犬猫食品上的应用 Download PDFInfo
- Publication number
- CN113519702A CN113519702A CN202110810281.7A CN202110810281A CN113519702A CN 113519702 A CN113519702 A CN 113519702A CN 202110810281 A CN202110810281 A CN 202110810281A CN 113519702 A CN113519702 A CN 113519702A
- Authority
- CN
- China
- Prior art keywords
- carrageen
- parts
- pos
- fucoidan
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000206575 Chondrus crispus Species 0.000 title claims abstract description 52
- 229920000855 Fucoidan Polymers 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 241000282326 Felis catus Species 0.000 title abstract description 26
- 235000013305 food Nutrition 0.000 title abstract description 10
- 229920001525 carrageenan Polymers 0.000 claims abstract description 27
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 27
- 210000003734 kidney Anatomy 0.000 claims abstract description 24
- 150000004676 glycans Chemical class 0.000 claims abstract description 23
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 23
- 239000005017 polysaccharide Substances 0.000 claims abstract description 23
- 230000002485 urinary effect Effects 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- UHWJJLGTKIWIJO-UHFFFAOYSA-L calcium iodate Chemical compound [Ca+2].[O-]I(=O)=O.[O-]I(=O)=O UHWJJLGTKIWIJO-UHFFFAOYSA-L 0.000 claims abstract description 11
- 241000283690 Bos taurus Species 0.000 claims abstract description 10
- 239000004151 Calcium iodate Substances 0.000 claims abstract description 10
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 10
- 235000019390 calcium iodate Nutrition 0.000 claims abstract description 9
- 235000020237 cranberry extract Nutrition 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 9
- 239000001488 sodium phosphate Substances 0.000 claims abstract description 9
- 229910000162 sodium phosphate Inorganic materials 0.000 claims abstract description 9
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims abstract description 9
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 8
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 8
- 238000001556 precipitation Methods 0.000 claims abstract description 7
- 238000003809 water extraction Methods 0.000 claims abstract description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 6
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 6
- 239000011575 calcium Substances 0.000 claims abstract description 6
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 6
- 239000011574 phosphorus Substances 0.000 claims abstract description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 6
- 240000007651 Rubus glaucus Species 0.000 claims abstract 2
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 6
- 230000000474 nursing effect Effects 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 5
- 241000282465 Canis Species 0.000 claims description 4
- 241000282324 Felis Species 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000012154 double-distilled water Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000007603 infrared drying Methods 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 238000010411 cooking Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 238000004537 pulping Methods 0.000 claims description 2
- 230000000630 rising effect Effects 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 238000007605 air drying Methods 0.000 claims 1
- 235000015278 beef Nutrition 0.000 claims 1
- 238000004042 decolorization Methods 0.000 claims 1
- 239000003480 eluent Substances 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 238000000967 suction filtration Methods 0.000 claims 1
- 235000005282 vitamin D3 Nutrition 0.000 claims 1
- 229940021056 vitamin d3 Drugs 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 10
- 230000003712 anti-aging effect Effects 0.000 abstract description 8
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 abstract description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 abstract description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 abstract description 3
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 abstract description 2
- 208000014001 urinary system disease Diseases 0.000 abstract description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract 1
- 229930182830 galactose Natural products 0.000 abstract 1
- 229930014626 natural product Natural products 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 16
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 229910006069 SO3H Inorganic materials 0.000 description 10
- 229960004397 cyclophosphamide Drugs 0.000 description 10
- 238000001514 detection method Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000008267 fucoses Chemical class 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 244000235659 Rubus idaeus Species 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 208000020832 chronic kidney disease Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 235000019629 palatability Nutrition 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 102100023410 Phospholipid hydroperoxide glutathione peroxidase Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 208000019206 urinary tract infection Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 description 3
- 206010061481 Renal injury Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 208000037806 kidney injury Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010007027 Calculus urinary Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000212297 Pelvetia Species 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 description 2
- 241000333599 Silvetia siliquosa Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 208000008281 urolithiasis Diseases 0.000 description 2
- NWGZOALPWZDXNG-LURJTMIESA-N (2s)-5-(diaminomethylideneamino)-2-(dimethylamino)pentanoic acid Chemical compound CN(C)[C@H](C(O)=O)CCCNC(N)=N NWGZOALPWZDXNG-LURJTMIESA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000195482 Fucaceae Species 0.000 description 1
- 241000195522 Fucales Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 102000007456 Peroxiredoxin Human genes 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 108010033024 Phospholipid Hydroperoxide Glutathione Peroxidase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000005255 Rubus parvifolius Species 0.000 description 1
- 235000018803 Rubus parvifolius Nutrition 0.000 description 1
- 108010060059 Sarcosine Oxidase Proteins 0.000 description 1
- 102000008118 Sarcosine oxidase Human genes 0.000 description 1
- 241000264279 Sargassum fusiforme Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NWWQJUISNMIVLJ-UHFFFAOYSA-N cyclotetrasulfur Chemical compound S1SSS1 NWWQJUISNMIVLJ-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- IFERABFGYYJODC-LURJTMIESA-N felinine Chemical compound OCCC(C)(C)SC[C@H](N)C(O)=O IFERABFGYYJODC-LURJTMIESA-N 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000015810 grayleaf red raspberry Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108030002458 peroxiredoxin Proteins 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical group 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/22—Compounds of alkali metals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/26—Compounds containing phosphorus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Sustainable Development (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种鹿角菜岩藻多糖的制备及其在犬猫食品上的应用。一种源自鹿角菜的多糖,名为鹿角菜岩藻多糖FT‑POS,通过水提醇沉法提取的新型鹿角菜岩藻多糖,结构以L‑岩藻糖和半乳糖组分为主,是一种全新的硫酸化的岩藻多糖,FT‑POS为天然产物。所述鹿角菜岩藻多糖FT‑POS的用途:用于制备犬猫的泌尿系统护理配方,水66‑70份、牛肾粉6‑20份、鹿角菜岩藻多糖FT‑POS0.5‑5份、蔓越莓提取物0.5‑2份、蓝莓提取物0.5‑2份、红树莓提取物0.5‑2份、维生素D30.1‑0.5份、碘酸钙0.5‑1份、磷酸钠0.5‑1份。其中鹿角菜多糖不超过口腔护理配方总质量的5%,配方中总钙和总磷的比例要在1:1~2:1之间。本发明能够有效预防泌尿系统疾病,改善肾脏炎症,提高肾脏抗衰老能力。
Description
技术领域
本发明属于犬猫泌尿系统保健品技术领域,特别是涉及鹿角菜岩藻多糖的制备及其在犬猫食品上的应用。
背景技术
猫下泌尿道综合征FLUTD是家猫最常见的疾病之一,FLUTD包括:①猫尿石症(urolithiasis),是指泌尿系统各部位结石或者结晶刺激导致炎症发生;②自发性膀胱炎(Feline idiopathic cystitis,FIC),FLUTD病例中,如果找不到导致临床症状特定的病因,则归类为自发性膀胱炎;③泌尿道感染,(Urinary tract infection, UTI),致病菌等病原体入侵泌尿道而引起的感染性疾病。引起FLUTD的主要原因有猫喝水少、生活环境卫生情况差以及年纪大免疫力低下等原因,其中喝水少是需要重点关注的,饲喂湿粮、设置多个饮水点、促进喝水的零食等都能改善猫不喝水的情况,FLUTD的预防要比治疗重要,做好预防很关键,目前关于FLUTD预防的产品多为处方粮和颗粒状的保健品,部分产品存在适口性差以及价格昂贵的情况,真正让猫能够主动进食的泌尿护理食品较少。
鹿角菜(Pelvetia siliquosa Tsenget C.F.Chang)隶属褐藻门(Phaeophyta)、圆子纲(Cyclosporeae)、鹿角菜目(Fucales)、鹿角菜科(Fucaceae)、鹿角菜属(Pelvetia),又名玉草、六角菜、羊栖菜。鹿角菜广泛分布在辽东半岛、山东、浙江等海域。鹿角菜中含有丰富的多糖,其中岩藻多糖是鹿角藻中重要的多糖成分之一,其主要单糖是L-岩藻糖,岩藻多糖因硫酸化程度、硫酸集团取代位置和分子水平不同所展现的功能也不同,目前关于鹿角菜的研究和应用也主要集中在鹿角菜多糖中的岩藻多糖,关于鹿角菜岩藻多糖的研究主要有抗氧化、抗肿瘤、降血脂血糖以及免疫力提升等研究方向,而岩藻多糖的提取工艺有水浴法、酸提取法、超声辅助法、水提醇沉法等,本专利通过水提醇沉法提取的新型硫酸化鹿角菜岩藻多糖研究报道较少,鹿角菜岩藻多糖再加上浓缩单宁酸、精氨酸以及钾等微量元素,具有潜在保护哺乳动物肾脏减少泌尿疾病发生的功能。
发明内容
为了克服现有技术的不足,本发明的目的是提供一种鹿角菜岩藻多糖的制备及其在犬猫食品上的应用。
一种含鹿角菜岩藻多糖的犬猫泌尿系统护理配方,包括以下质量份数的原料,水66-90份、牛肾冻干粉6-20份、鹿角菜岩藻多糖FT-POS0.5-5份、蔓越莓提取物0.5-2份、蓝莓提取物0.5-2份、红树莓提取物0.5-2份、维生素D30.1-0.5份、碘酸钙0.5-1份、磷酸钠0.5-1份,精氨酸0.1-0.5份。
所述的牛肾冻干粉由新鲜牛肾进过粗磨成浆、过筛、高温蒸煮、精磨和均质处理,最后通过冷冻干燥后进一步精细粉碎而成。
所述维生素D族为维生素D3 。
所述的犬猫泌尿系统护理配方中鹿角菜岩藻多糖FT-POS制备方法为水提醇沉法,所述岩藻多糖FT-POS提取自鹿角菜,先通过水提醇沉法(乙醇沉淀多糖,乙醇、丙酮和乙醚分别洗涤)粗提鹿角菜多糖,经离子交换层析柱分离获得多个糖组分,并对所属多个糖组分进行脱盐纯化,最后通过液相色谱仪进行单糖组分分析得到硫酸化岩藻多糖。
一种所述的泌尿系统护理配方的制备方法:
①称重:所有原料按照配方所述比例称重,121℃高温杀菌30分钟;
②预混:将配好的原料牛肾粉、鹿角菜岩藻多糖FT-POS、蔓越莓提取物、蓝莓提取物、红树莓提取物、维生素D3、碘酸钙、磷酸钠进行预混搅拌;
③升温:加水升温(37-40℃),静置2小时,将预混料继续升温至80-85℃,静置1小时;
④均质:预混料进行均质处理,冷却到常温。
⑤成型:将预混料进行灌装、密封、杀菌、风干,每罐10ml。
本发明的有益效果:具体如表1:
表1. 各成分功能
成分 | 功能 |
牛肾冻干粉 | 补充微量元素,促进新陈代谢 |
鹿角菜岩藻多糖FT-POS | 增强肾脏抗衰老功能 |
蔓越莓提取物 | 富含浓缩单宁酸,具有抗细菌黏附特性。能阻止大肠杆菌等致病菌黏附在尿道的上皮细胞和膀胱壁上,使致病菌随着尿液流出,有助于减少尿路感染的发生。 |
蓝莓提取物 | 蓝莓提取物中富含的花青素和单宁酸有助于抑制引起尿道感染。 |
小红莓提取物 | 小红莓提取物中富含鞣花单宁,有利于改善健康犬猫的血管功能还具有抗氧化抗衰老的功能。 |
碘酸钙 | 补充钙元素,调整总钙和总磷比在1:1与2:1之间,保证犬猫养分能够正常吸收,减少钙磷比失调造成的泌尿系统疾病。 |
磷酸钠 | 补充磷元素,调整总钙和总磷比在1:1与2:1之间,保证配方中的养分能够被犬猫正常吸收,减少钙磷比失调造成的泌尿系统疾病。 |
维生素D<sub>3</sub> | 促进钙的吸收。 |
精氨酸 | 精氨酸是尿素循环中的关键中间体,能刺激尿素合成并激活酶,使氨解毒合成尿素。 |
附图说明
图1是鹿角菜岩藻多糖FT-POS结构图。
图2是鹿角菜岩藻多糖FT-POS的电喷雾质谱检测图。
图3是HE染色图:鹿角菜岩藻多糖FT-POS缓解环磷酰胺(CYX)诱导的小鼠肾小管坏死。
图4是TUNEL染色图:鹿角菜岩藻多糖FT-POS缓解环磷酰胺(CYX)诱导的小鼠肾脏细胞凋亡水平。
图5是鹿角菜岩藻多糖FT-POS能恢复被CYX(环磷酰胺)抑制的GSH-PX酶活以及能抑制CYX造成的细胞丙二醛(MDA)升高。
图6是鹿角菜岩藻多糖FT-POS能够提高小鼠肾脏抗衰老蛋白(Klotho)和抗氧化蛋白谷胱甘肽过氧化物酶4(GPX4)表达图。
具体实施方式
以下结合附图和实施例对本发明做进一步的阐述。
实施例1、鹿角菜岩藻多糖FT-POS提取以及结构分析
①脱色处理:新鲜鹿角菜用85%乙醇的脱色三次,使橄榄绿颜色变浅,得到色素较低的鹿角菜;②水提醇沉法提取多糖:热水加压多糖,维持温度为105 ℃提取3-4h,直到上清液澄清,用硅藻土抽滤得到含有粗多糖的上清液,将上清液分装至试管中,用8000rpm离心5分钟得到上清浓缩液。对上清浓缩液进行透析,3600Da透析袋透析24小时,红外烘干灯烘干后得到鹿角菜粗多糖。③鹿角菜粗多糖的分离及纯化:取鹿角菜粗多糖若干克,先通过DEAE-Bio Gel Agarose FF gel双蒸水洗脱收集后再用0.9%的NaCl溶液梯度洗脱收集洗脱液3-5次,红外烘干后得到纯化的硫酸化鹿角菜多糖FT-POS,经组分结构分析后发现,该多糖主题为岩藻多糖。由此得到FT-POS为目标多糖即鹿角菜岩藻多糖,命名为鹿角菜岩藻多糖FT-POS;④鹿角菜岩藻多糖FT-POS水解组分制备:将FT-POS溶于双蒸水后,用阳离子交换树脂充分混匀水解2.5-3小时,经浓缩、透析、冻干之后得到硫酸化岩藻多糖FT-POS;⑤鹿角菜岩藻多糖FT-POS结构分析:用电喷雾质谱检测、核磁共振检测等方法分析FT-POS 结构。
试验结果如下,结构预测(图1)、电喷雾质谱(图2和表2)分析,FT-POS具有岩藻糖骨架以及少量的半乳糖醛酸,此外,根据离子组分析表(表2),FT-POS具有不同硫酸化的岩藻糖低聚物,包括单硫、双硫、三硫、四硫、五硫等,具体分别是单硫酸化的岩藻糖低聚物 (m/z 243.027(-1), 389.090(-1)和535.130(-1) ),双硫酸化的岩藻糖低聚物(m/z234.021 (-2) 和 307.053 (-2)), 三硫酸化的岩藻糖低聚物(m/z 333.054 (-3)),双、三、四、五硫酸化的岩藻糖低聚物(m/z 315.050 (-2), 285.039 (-3), 270.033 (-4) 和261.230 (-5)),FT-POS主要结构是硫酸化岩藻糖低聚物(单硫或者双硫)以及硫酸化半乳岩藻糖低聚物(四硫),是一种全新的鹿角菜岩藻多糖。
表2.鹿角菜岩藻多糖FT-POS离子组成
质子数/电荷数(m/z) | 电荷数 | 组分 |
234.021 | 2 | [Fuc2(SO3H)2-2H]2- |
243.027 | 1 | [Fuc(SO3H)-H]- |
261.230 | 5 | [GalFuc5(SO3H)5-5H]5- |
270.033 | 4 | [GalFuc4(SO3H)4-4H]4- |
285.039 | 3 | [GalFuc3(SO3H)3-3H]3- |
307.053 | 2 | [Fuc3(SO3H)2-2H]2- |
315.050 | 2 | [GalFuc2(SO3H)2-2H]2- |
333.054 | 3 | [Fuc4(SO3H)5-3H]3- |
389.090 | 1 | [Fuc2(SO3H)-H]- |
535.130 | 1 | [Fuc3(SO3H)-H]- |
注:m/z是质子数/电荷数的比值。质荷比(mass-to-charge ratio)是质谱分析中的一个重要参数。
实施例2、细胞水平上揭示鹿角菜岩藻多糖FT-POS缓解肾脏细胞凋亡的作用机理
由于涉及到肾脏样品的采样,需要解剖,故不采用犬猫作为实验。实验选用环磷酰胺CTX免疫抑制小鼠模型,小鼠品系为C57BL/6,5周龄,雄性60只,初始平均体重22.12g,给药浓度为80mg/kg,每只给药约1.6mg/d,按给药100ul计算需配置成16mg/ml母液,生理盐水溶解,漩涡震荡混匀,过滤除菌,每次腹腔注射100ul。
实验分组如表3
表3. 实验分组
组别 | 处理方式 | 数量(只) | 周期(天) |
空白对照组(生理盐水) | 小鼠腹腔内连续7天生理盐水0.1ml | 20(n=4) | 7 |
模型组(环磷酰胺CYX) | 在3-5日时,向小鼠灌胃CYX环磷酰胺(80 mg/kg/d) | 20(n=4) | 7 |
实验组(多糖+CYX环磷酰胺(80 mg/kg/d)) | 在3-5天向小鼠灌胃CYX,在此基础上连续7天向小鼠腹腔注射鹿角菜多糖FT-POS | 20(n=4) | 7 |
临床观察包含死亡数,一般健康状况和毒性症状。每日上午和下午各分别密切观察动物的状态(包含皮肤及背毛状态,眼睛及粘膜,呼吸系统,循环系统,自主运动,中枢神经系统及行为特点),详细记录不良反应的特征,发生的时间,严重程度以及动物死亡情况等。
实验记录:每组小鼠从喂食第一天起观察小鼠健康状况,统计死亡数、采食量、体重等。
肾脏样品采集: 实验结束后,处死小鼠,采集肾脏液氮速冻后存放于-80度待用。
试验结果如下,对不同组的小鼠肾小管进行HE染色发现(图3所示),环磷酰胺(CYX)处理之后,肾小管出现水肿的情况,经FT-POS处理肾小管的水肿情况得到了明显的缓解,说明鹿角菜岩藻多糖FT-POS缓解环磷酰胺(CYX)诱导的小鼠肾小管坏死,通过进一步对肾脏细胞进行TUNEL染色发现(图4所示),相比于对照组,CYX处理之后肾脏细胞凋亡水平明显增加,具体表现为棕色点增多,相比于CYX组,经过FT-POS处理肾脏细胞的凋亡得到了缓解。同时,ELISA试剂盒检测发现鹿角菜岩藻多糖FT-POS能恢复被CYX(环磷酰胺)抑制的GSH-PX酶活以及能抑制CYX造成的细胞丙二醛(MDA)升高(图5所示)。综上所述,在细胞水平上,鹿角菜岩藻多糖FT-POS一定程度上能够缓解肾脏细胞凋亡。
实施例3、分子水平上揭示鹿角菜岩藻多糖FT-POS提高肾脏细胞抗氧化抗衰老的作用机理
①用全蛋白提取试剂盒提取小鼠肾脏蛋白(包括对照组、模型组和试验组),将蛋白粗提液进行离心分装,将含有蛋白的上清装入干净的离心管,用于后续试验;
②提完蛋白后进行浓度测定和稀释变性,蛋白浓度检测方法参照BCA蛋白浓度试剂盒说明书,根据酶标仪数值算出各组蛋白样品的蛋白浓度,然后对各样品浓度进行调节:根据之前计算得到的检测结果,用Lysis buffer将各样品稀释到同一浓度,并加入4xLoading buffer,95℃恒温加热10 min使蛋白变性,冰上静置冷却后于-20℃保存。
③将稀释好的样品最后进行 Western blot检测,具体包括蛋白电泳、转膜和抗体反应
④上机,进行完抗体反应之后,将膜放入凝胶成像分析系统,滴加发光液显影,进行观察拍照。试验以GAPDH为内参,检测肾脏抗衰老蛋白Klotho、抗氧化蛋白GPX4以及PRX5的表达水平。
试验结果如下:结果如图6所示,相比于对照组,经过CYX处理之后,肾脏抗衰老蛋白Klotho表达量显著下降,注射了鹿角菜岩藻多糖FT-POS则使Klotho表达量显著提高,说明鹿角菜岩藻多糖FT-POS能够提高CYX引起的肾脏抗衰老蛋白的降低。同样,相对于对照组,经过CYX处理之后,抗氧化蛋白谷胱甘肽过氧化物酶GPX4表达量显著下降,注射了鹿角菜岩藻多糖FT-POS则使GPX4表达量显著提高,不过对另一抗氧化蛋白Peroxiredoxin5(PRX5)无显著影响,总体在分子水平上,鹿角菜岩藻多糖FT-POS能够提高CYX引起的肾脏抗氧化能力的降低。
实施例4、含鹿角菜岩藻多糖FT-POS护理配方制备以及应用效果
①不同配比的配方打样
样品配方一:水分90份、牛肾冻干粉6份、鹿角菜岩藻多糖FT-POS0.5份、蔓越莓提取物0.5份、蓝莓提取物0.5份、红树莓提取物0.5份、维生素D30.1份、碘酸钙0.5份、磷酸钠0.5份,精氨酸0.1份。
样品配方二:水分76份、牛肾冻干粉14份、鹿角菜岩藻多糖FT-POS 2.5份、蔓越莓提取物1.5份、蓝莓提取物1.5份、红树莓提取物1.5份、维生素D3 0.2份、碘酸钙0.8份、磷酸钠0.7份,精氨酸0.3份。
样品配方三:水分66份、牛肾冻干粉20份、鹿角菜岩藻多糖FT-POS 5份、蔓越莓提取物2份、蓝莓提取物2份、红树莓提取物2份、维生素D30.5份、碘酸钙1份、磷酸钠1份,精氨酸0.5份。
③按照三个配方分别进行配置打样,然后进行感官、适口性测定,选择一个配方进行下一步饲喂试验。
④根据病史、临床症状、临床化验以及B超等检测结果,选取18只猫分成两组,每组9只猫,健康组和慢性肾功能衰竭组(CRF),统一喂A品牌猫粮(低镁含量),饲喂环境一致,试验周期2周,每天每只猫补充10ml泌尿样品,实验前后采血,统计初末体重。采用ELISA试剂盒、肌氨酸氧化酶法、尿素酶-谷氨酸脱氢酶法分别测定血清中慢性肾功能损伤相关指标二甲基精氨酸(SDMA)、尿素氮(Urea)、肌酐(Crea)、总蛋白(TP)和白蛋白(ALB)浓度浓度,整个取血过程中都在有资质的宠物医院进行,由专业兽医人员进行取样,对猫的应激作用减少到最低。
表4.不同组猫血清生化指标结果
配方评估结果如下,配方一适口性良好,浓稠度较稀,配方二同样适口性较好,浓度适中,配方三较粘稠,猫舔舐存在一定困难,粘牙,其原因可能是岩藻多糖含量高从而增加了粘稠性。综合考虑,三个配方中选择配方二进行饲喂试验,选择原因是配方二在保持适口性较好的同时有效成分含量比配方一高。
饲喂结果如下:健康组在每日饲喂10ml配方二14天后,肾脏损伤相关指标无明显变化,血清中ALB和TP一定程度降低,分别降低了3.4%和6.0%,且在合理范围内,但总体上不明显,健康组体重无明显变化。CRF组在饲喂10ml配方二14天后,体重无明显变化,部分肾脏损伤相关指标有明显降低,其中SDMA降低了2.2%(无明显变化),Urea降低了7.7%,Crea降低了9.3%,TP降低了10.6%,ALB降低了8.5%,体重略微增加。说明泌尿系统护理配方能够一定程度上缓解慢性肾脏衰竭情况,但总体上肾脏损伤相关指标均高于正常值范围,属于亚健康状态,含鹿角菜岩藻多糖FT-POS的泌尿护理配方对肾脏衰竭具有一定的预防作用,对出现肾脏衰竭的猫具有一定的改善作用,但无法彻底根治,所以该配方相关产品定义为功能性食品,辅助或者预防泌尿相关疾病,并非药用。本试验提供了一个泌尿系统护理的参考案例,适用于泌尿系统损伤或者存在功能性衰退的猫(例如老年猫),若需彻底治疗,需要服用相关药物或者处方粮。
上述试验结果和实施例是对本发明的具体描述,但是本发明不仅局限于上述的具体实施方式,上述试验结果仅仅是部分配方的配比和产品形态,并不是限制在这些配比和形态当中,同样的配比可以做成不同形态(冻干、粉剂、胶囊、液体)的产品。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动,本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。本发明的保护范围由所附权利要求及其任何等同物给出。
Claims (6)
1.一种含鹿角菜岩藻多糖FT-POS的犬猫泌尿系统护理配方,其特征在于:按质量份,水66-90份、牛肾冻干粉6-20份、鹿角菜岩藻多糖FT-POS 0.5-5份、蔓越莓提取物0.5-2份、蓝莓提取物0.5-2份、红树莓提取物0.5-2份、维生素D3 0.1-0.5份、碘酸钙0.5-1份、磷酸钠0.5-1份、精氨酸0.1-0.5份。
2.根据权利要求1所述的犬猫泌尿系统护理配方,其特征在于:所述的牛肾粉由新鲜牛肾经过粗磨成浆、过筛、高温蒸煮、精磨和均质处理,最后在负20℃的环境下,粉碎成100目的精细牛肾冻干粉。
3.根据权利要求1所述的犬猫泌尿系统护理配方,其特征在于:所添加的碘酸钙和磷酸钠中总钙和总磷的质量比例在1:1~2:1。
4.根据权利要求1所述的犬猫泌尿系统护理配方,其特征在于:所述的维生素D3含量不超过总质量的0.5%。
5.一种鹿角菜岩藻多糖的制备方法,其特征在于:所述鹿角菜岩藻多糖提取自鹿角菜,提取方法为水提醇沉法,具体如下:
①脱色处理:新鲜鹿角菜用85%乙醇的脱色三次,得到色素较低的鹿角菜;
②水提醇沉法提取粗多糖:热水加压脱色处理后的鹿角菜,105 ℃提取3-4h,直到上清液澄清,用硅藻土抽滤得到含有粗多糖的上清液,用8000rpm离心5分钟得到上清浓缩液;3600Da透析袋透析24小时,红外烘干灯烘干后得到鹿角菜粗多糖;
③鹿角菜粗多糖的分离及纯化:取鹿角菜粗多糖若干克,先通过DEAE-Bio GelAgarose FF gel双蒸水洗脱收集后再用0.9%的NaCl溶液梯度洗脱收集洗脱液3-5次,红外烘干后得到纯化的硫酸化鹿角菜多糖FT-POS(Furrytail—Pelvetia oligoses)。
6.一种根据权利要求书1所述的犬猫泌尿系统护理配方的制备方法,其特征在于:
①称重:所有原料按照配方所述比例称重,121℃高温杀菌30分钟;
②预混:将配好的原料牛肾粉、鹿角菜岩藻多糖FT-POS、蔓越莓提取物、蓝莓提取物、红树莓提取物、维生素D3、碘酸钙、磷酸钠进行预混搅拌;
③升温:加水升温至37-40℃,静置2小时,将预混料继续升温至80-85℃,静置1小时;
④均质:预混料进行均质处理,冷却到常温;
⑤成型:将预混料进行灌装、密封、杀菌、风干。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110810281.7A CN113519702A (zh) | 2021-07-17 | 2021-07-17 | 鹿角菜岩藻多糖的制备及其在犬猫食品上的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110810281.7A CN113519702A (zh) | 2021-07-17 | 2021-07-17 | 鹿角菜岩藻多糖的制备及其在犬猫食品上的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113519702A true CN113519702A (zh) | 2021-10-22 |
Family
ID=78128510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110810281.7A Pending CN113519702A (zh) | 2021-07-17 | 2021-07-17 | 鹿角菜岩藻多糖的制备及其在犬猫食品上的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113519702A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104910285A (zh) * | 2015-05-19 | 2015-09-16 | 汕头大学医学院 | 一种新的鹿角海萝多糖 |
CN105558386A (zh) * | 2015-12-29 | 2016-05-11 | 青岛北斗星云通信科技有限公司 | 一种预防泌尿系统疾病的猫粮 |
CN106309470A (zh) * | 2016-08-30 | 2017-01-11 | 闫滨 | 一种羊栖菜多糖的应用 |
CN106727729A (zh) * | 2016-12-18 | 2017-05-31 | 钦州学院 | 一种从海藻中综合提取岩藻黄质和岩藻多糖粗品的方法 |
CN106727265A (zh) * | 2016-12-16 | 2017-05-31 | 广东芭薇生物科技股份有限公司 | 一种含褐藻提取物的组合物及其应用 |
CN109369816A (zh) * | 2018-09-10 | 2019-02-22 | 浦江县昂宝生物技术有限公司 | 羊栖菜抗衰老多糖的提取方法 |
CN109393147A (zh) * | 2018-12-29 | 2019-03-01 | 上海汉维生物医药科技有限公司 | 一种维护犬猫泌尿道健康的组合物及其制备方法 |
CN111789195A (zh) * | 2020-08-04 | 2020-10-20 | 辽宁海辰宠物有机食品有限公司 | 一种单一肉源低敏无谷的犬猫用冻干混合零食及其制备方法和应用 |
-
2021
- 2021-07-17 CN CN202110810281.7A patent/CN113519702A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104910285A (zh) * | 2015-05-19 | 2015-09-16 | 汕头大学医学院 | 一种新的鹿角海萝多糖 |
CN105558386A (zh) * | 2015-12-29 | 2016-05-11 | 青岛北斗星云通信科技有限公司 | 一种预防泌尿系统疾病的猫粮 |
CN106309470A (zh) * | 2016-08-30 | 2017-01-11 | 闫滨 | 一种羊栖菜多糖的应用 |
CN106727265A (zh) * | 2016-12-16 | 2017-05-31 | 广东芭薇生物科技股份有限公司 | 一种含褐藻提取物的组合物及其应用 |
CN106727729A (zh) * | 2016-12-18 | 2017-05-31 | 钦州学院 | 一种从海藻中综合提取岩藻黄质和岩藻多糖粗品的方法 |
CN109369816A (zh) * | 2018-09-10 | 2019-02-22 | 浦江县昂宝生物技术有限公司 | 羊栖菜抗衰老多糖的提取方法 |
CN109393147A (zh) * | 2018-12-29 | 2019-03-01 | 上海汉维生物医药科技有限公司 | 一种维护犬猫泌尿道健康的组合物及其制备方法 |
CN111789195A (zh) * | 2020-08-04 | 2020-10-20 | 辽宁海辰宠物有机食品有限公司 | 一种单一肉源低敏无谷的犬猫用冻干混合零食及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
闫旭: "巨藻LN岩藻多糖对糖尿病大鼠护肾功效机理的研究", 中国优秀硕士学位论文全文数据库医药卫生科技辑, no. 8, 15 August 2017 (2017-08-15), pages 38 - 46 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104138469A (zh) | 治疗ii型糖尿病和逆转胰岛素抵抗的药物复合制剂及其制备方法 | |
CN104367987A (zh) | 兽用黄芪制剂及其制备方法 | |
CN112250774B (zh) | 一种南瓜多糖铬硒配合物的制备方法及其制品和应用 | |
CN113519702A (zh) | 鹿角菜岩藻多糖的制备及其在犬猫食品上的应用 | |
CN107303386A (zh) | 一种用于治疗白细胞低下的口服液的制备方法 | |
CN103920140B (zh) | 一种人用降糖减肥降脂复方制剂 | |
WO2016141774A1 (zh) | 吉林人参低聚肽在制备改善和增强性功能的食品或保健食品中的用途 | |
CN109364085A (zh) | 白芨寡糖及其组合物在调节糖脂代谢紊乱中的应用 | |
CN105597080A (zh) | 一种用于治疗尿毒症和尿蛋白的药物 | |
CN110404021B (zh) | 一种黄精制剂及制备方法 | |
CN107778332A (zh) | 唾液酸低聚糖及其制造方法、生发和骨骼肌形成促进剂 | |
CN106928376A (zh) | 山茱萸多糖的分离方法及其应用 | |
CN102816226A (zh) | 一种猪小肠抗菌肽pr39的制备方法 | |
CN105558350A (zh) | 一种含有中草药复合粗多糖的饲料及其制备方法 | |
CN101167887A (zh) | 口服治疗糖尿病肾病的枸杞单方中药及其制备方法 | |
CN105232678A (zh) | 一种提高蛋鸡产蛋量的中药颗粒剂及其制备方法 | |
CN104367871B (zh) | 一种防治生猪胃肠炎的益生菌发酵中药制剂及其制备工艺 | |
CN116211981B (zh) | 一种含有沉香的治疗牙龈肿痛改善口腔菌群的复方制剂 | |
CN108743693A (zh) | 一种仔猪保健促生长中药组合物、制备方法及其应用 | |
CN111732672B (zh) | 一种具有降尿酸功效的黄秋葵聚半乳糖醛酸及其制备方法和用途 | |
CN103750330B (zh) | 一种含有牛骨髓粉的口服组合物及其制备方法 | |
CN116036174B (zh) | 一种治疗肺结节的药物及其制备方法 | |
CN114712481B (zh) | 一种复合植物源多肽及其制备方法与应用 | |
CN116585379B (zh) | 一种用于防治高尿酸血症及痛风的中药组合物、方法及应用 | |
CN100497650C (zh) | 一种富锌亮菌多糖及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |